Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...

Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

Omeros announces positive results from a pivotal narsoplimab trial in TA-TMA, showing significant survival benefits and ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...

Narsoplimab, also known as OMS721, is a monoclonal antibody targeting MASP-2, a key enzyme in the lectin pathway of complement. The FDA has granted the drug breakthrough therapy and orphan drug ...

Surgical robotics pioneer Andromeda Surgical today announced a groundbreaking milestone: Dr. Cristián Trucco of Universidad Católica performed the world's first robotic-assisted holmium laser ...

Each of the three major complement activation pathways (Classical, CP; Alternative, AP and Lectin, LP) employs specific recognition molecules and initiating serine proteases. All of them converge into ...

the key and most proximal activator of the alternative pathway of complement, were presented at the 66th Annual Meeting of the American Society of Hematology (ASH) yesterday in San Diego.

The NFL has announced its International Player Pathway (IPP) program Class of 2025 featuring 14 athletes representing 13 nations around the world, as the league continues to focus on creating more ...

Some students trying to enroll in classes in Brigham Young University-Pathway Worldwide are experiencing the unpleasant shock of being unable to do so and, in some cases, discovering that classes ...